Bioserv Corporation
Bioserv manufactures injectable pharmaceuticals. 2015E revenues $4MM and EBITDA positive. Bioserv has a compelling growth and investment opportunity as a 503B outsourcer – a new FDA category after 60 people died in 2012 due to contaminated drugs.
Bioserv was established in 1988. It is a contract manufacturer of injectable pharmaceuticals. Bioserv will finish 2015 with approximately $4MM in revenues and breakeven. It plans to register as a 503B outsourcer, a new FDA regulatory category created after the NECC disaster. Contaminated drugs manufactured by NECC killed over sixty people in 2012. See Newsweek cover story for 4/24/15 – KILLER PHARMACY: Inside a Medical Mass Murder Case. The largest 503B outsourcer, PharMedium, was recently acquired by Amerisource Bergen for over 6x revenues and 26x EBITDA. Bioserv believes the 503B space offers an outstanding growth and investment opportunity.
Products / Services
Manufacture of Injectable Pharmaceuticals
Management
Chief Executive Officer
Albert Hansen
Bioserv manufactures injectable pharmaceuticals. 2015E revenues $4MM and EBITDA positive. Bioserv has a compelling growth and investment opportunity as a 503B outsourcer – a new FDA category after 60 people died in 2012 due to contaminated drugs.
See Campaign: https://www.equitynet.com/c/bioserv-corporation
Contact Information:
Chief Executive Officer
Albert Hansen
Tags:
EquityNet, Equity, United States, Men, Family, Consumer, Teens, Women, English, Health and Nutrition, Healthcare, California, Medical & Healthcare, Industry verticals, Regions, Types of Crowdfunding deal, Language
The post Bioserv Corporation is a contract manufacturer of injectable pharmaceuticals appeared first on iCrowdNewswire.
Source: Icrowdnewswire
